Literature DB >> 26139058

Atrial Fibrillation Activates AMP-Dependent Protein Kinase and its Regulation of Cellular Calcium Handling: Potential Role in Metabolic Adaptation and Prevention of Progression.

Masahide Harada1, Artavazd Tadevosyan2, Xiaoyan Qi2, Jiening Xiao2, Tao Liu3, Niels Voigt4, Matthias Karck5, Markus Kamler6, Itsuo Kodama7, Toyoaki Murohara8, Dobromir Dobrev4, Stanley Nattel9.   

Abstract

BACKGROUND: Atrial fibrillation (AF) is associated with metabolic stress, which activates adenosine monophosphate-regulated protein kinase (AMPK).
OBJECTIVES: This study sought to examine AMPK response to AF and associated metabolic stress, along with consequences for atrial cardiomyocyte Ca(2+) handling.
METHODS: Calcium ion (Ca(2+)) transients (CaTs) and cell shortening (CS) were measured in dog and human atrial cardiomyocytes. AMPK phosphorylation and AMPK association with Ca(2+)-handling proteins were evaluated by immunoblotting and immunoprecipitation.
RESULTS: CaT amplitude and CS decreased at 4-min glycolysis inhibition (GI) but returned to baseline at 8 min, suggesting cellular adaptation to metabolic stress, potentially due to AMPK activation. GI increased AMPK-activating phosphorylation, and an AMPK inhibitor, compound C (CompC), abolished the adaptation of CaT and CS to GI. The AMPK activator 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) increased CaT amplitude and CS, restoring CompC-induced CaT and CS decreases. CompC decreased L-type calcium channel current (ICa,L), along with ICa,L-triggered CaT amplitude and sarcoplasmic reticulum (SR) Ca(2+) content under voltage clamp conditions in dog cells and suppressed CaT and ICa,L in human cardiomyocytes. Small interfering ribonucleic acid-based AMPK knockdown decreased CaT amplitude in neonatal rat cardiomyocytes. L-type Ca(2+) channel α subunits coimmunoprecipitated with AMPKα. Atrial AMPK-activating phosphorylation was enhanced by 1 week of electrically maintained AF in dogs; fractional AMPK phosphorylation was increased in paroxysmal AF and reduced in longstanding persistent AF patients.
CONCLUSIONS: AMPK is activated by metabolic stress and AF, and helps maintain the intactness of atrial ICa,L, Ca(2+) handling, and cell contractility. AMPK contributes to the atrial compensatory response to AF-related metabolic stress; AF-related metabolic responses may be an interesting new therapeutic target.
Copyright © 2015 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell calcium handling; heart pharmacology; myocardial energy metabolism

Mesh:

Substances:

Year:  2015        PMID: 26139058     DOI: 10.1016/j.jacc.2015.04.056

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  32 in total

1.  Deciphering the fundamental mechanisms of atrial fibrillation: a quest for over a century.

Authors:  Stanley Nattel; Dobromir Dobrev
Journal:  Cardiovasc Res       Date:  2016-02-07       Impact factor: 10.787

2.  Class I Histone Deacetylase Inhibition for the Treatment of Sustained Atrial Fibrillation.

Authors:  Mitsuru Seki; Ryan LaCanna; Jeffery C Powers; Christine Vrakas; Fang Liu; Remus Berretta; Geena Chacko; John Holten; Pooja Jadiya; Tao Wang; Jeffery S Arkles; Joshua M Copper; Steven R Houser; Jianhe Huang; Vickas V Patel; Fabio A Recchia
Journal:  J Pharmacol Exp Ther       Date:  2016-06-27       Impact factor: 4.030

3.  Resveratrol prevents atrial fibrillation by inhibiting atrial structural and metabolic remodeling in collagen-induced arthritis rats.

Authors:  Yun Zhang; Song Zhang; Zonghong Liu; Xinbo Zhao; Yue Yuan; Li Sheng; Yue Li
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-08-22       Impact factor: 3.000

Review 4.  Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation.

Authors:  Stanley Nattel; Dobromir Dobrev
Journal:  Nat Rev Cardiol       Date:  2016-08-04       Impact factor: 32.419

5.  Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway.

Authors:  Guang-Zhong Liu; Ting-Ting Hou; Yue Yuan; Peng-Zhou Hang; Jing-Jing Zhao; Li Sun; Guan-Qi Zhao; Jing Zhao; Jing-Mei Dong; Xiao-Bing Wang; Hang Shi; Yong-Wu Liu; Jing-Hua Zhou; Zeng-Xiang Dong; Yang Liu; Cheng-Chuang Zhan; Yue Li; Wei-Min Li
Journal:  Br J Pharmacol       Date:  2016-02-18       Impact factor: 8.739

Review 6.  Perspectives and challenges of antioxidant therapy for atrial fibrillation.

Authors:  Iveta Gasparova; Peter Kubatka; Radka Opatrilova; Martin Caprnda; Slavomira Filipova; Luis Rodrigo; Leone Malan; Ioana Mozos; Miroslava Rabajdova; Vladimir Nosal; Nazarii Kobyliak; Vanda Valentova; Daniel Petrovic; Mariusz Adamek; Peter Kruzliak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-29       Impact factor: 3.000

Review 7.  Effect of antidiabetic drugs on the risk of atrial fibrillation: mechanistic insights from clinical evidence and translational studies.

Authors:  Ting-Wei Lee; Ting-I Lee; Yung-Kuo Lin; Yao-Chang Chen; Yu-Hsun Kao; Yi-Jen Chen
Journal:  Cell Mol Life Sci       Date:  2020-09-23       Impact factor: 9.261

Review 8.  The value of basic research insights into atrial fibrillation mechanisms as a guide to therapeutic innovation: a critical analysis.

Authors:  Jordi Heijman; Vincent Algalarrondo; Niels Voigt; Jonathan Melka; Xander H T Wehrens; Dobromir Dobrev; Stanley Nattel
Journal:  Cardiovasc Res       Date:  2015-12-23       Impact factor: 10.787

Review 9.  Atrial remodelling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal.

Authors:  Olurotimi O Mesubi; Mark E Anderson
Journal:  Cardiovasc Res       Date:  2016-01-13       Impact factor: 10.787

10.  Atrial fibrillation rhythm is associated with marked changes in metabolic and myofibrillar protein expression in left atrial appendage.

Authors:  Julie H Rennison; Ling Li; Cheryl R Lin; Beth S Lovano; Laurie Castel; Sojin Youn Wass; Catherine C Cantlay; Meghan McHale; A Marc Gillinov; Reena Mehra; Belinda B Willard; Jonathan D Smith; Mina K Chung; John Barnard; David R Van Wagoner
Journal:  Pflugers Arch       Date:  2021-01-16       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.